Biogen Inc (BIIB) - News Archive

A Leap Forward in Alzheimer s Treatment: Biogen and Eisai s Innovations Garner Global Recognition Biogen Inc. and Eisai Co., Ltd., two of the most pioneering companies in the pharmaceutical landscape, have achieved rema...

Biogen s Regulatory Challenge and Financial Dynamics: A Complex Interplay Regulatory Update on Nusinersen s High Dose Regimen Biogen Inc. recently faced regulatory scrutiny as the U.S. Food and Drug Administration (FDA)...

Breakthrough Developments in Lupus and Kidney Transplant Treatments: Dapirolizumab Pegol and Felzartamab Lead the WayIn recent pivotal advancements within the field of immunology, Biogen Inc. (NASDAQ: BIIB) and UCB (Eur...

In a significant move to enhance its portfolio of therapeutic options, Biogen Inc. has announced a strategic research collaboration with City Therapeutics to develop innovative RNA interference (RNAi)-based therapies. T...

Biogen Inc. a renowned leader in biopharmaceuticals, is embarking on an ambitious journey that could reshape the landscape of both its operational infrastructure and its contributions to the medical sciences. On March 2...

In a rapid evolution of therapeutic prospects, the biopharmaceutical landscape is witnessing significant strides with the recent regulatory reviews and designations surrounding promising treatments. Notably, recent anno...

Biogen Inc. has recently made waves in the biopharmaceutical landscape with its innovative drug LEQEMBI (lecanemab-irmb), following the FDA s acceptance of its Biologics License Application (BLA) for subcutaneous mainte...

Advancements in Lupus and SMA Treatments: A Double-Edged Sword for Biogen and UCB : Recent presentations at significant medical congresses have unveiled promising developments in the treatments of systemic lupus erythem...

Biogen s Breakthrough Journey: Felzartamab s Promise in Tackling Antibody-Mediated Rejection in Kidney Transplants In a significant development for kidney transplant recipients, Biogen Inc. has announced that its invest...

Exploring New Frontiers in Spinal Muscular Atrophy Management: Insights from the DEVOTE Study on Higher-Dose Nusinersen Recent advancements in the treatment of spinal muscular atrophy (SMA) are shifting paradigms and of...

Promising Phase 3 Results for Dapirolizumab Pegol in Systemic Lupus ErythematosusIn a significant development within the biopharmaceutical industry, UCB and Biogen Inc. recently announced positive topline results from t...

The release of positive topline data by Biogen Inc. (Nasdaq: BIIB) from the Phase 2/3 DEVOTE study represents a crucial advancement in the treatment landscape for spinal muscular atrophy (SMA). Announced on September 4,...

In a significant step forward for Alzheimer’s disease (AD) research, Biogen Inc. (Nasdaq: BIIB), Beckman Coulter, Inc., and Fujirebio have announced a collaborative effort aimed at identifying and developing blood-based...

Biogen Partners with Beckman Coulter and Fujirebio to Advance Blood Biomarkers for Tauopathies in Alzheimer s Disease Amid Competitive Market DynamicsIn a significant development in the fight against Alzheimer s disease...

In a recent announcement, Eisai Co., Ltd. and Biogen Inc. revealed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has rejected the Marketing Authorization Approval...

BIIB Investors Face Securities Fraud Lawsuits Amidst Competitive Challenges in 2024Biogen Inc, a renowned pharmaceutical company, is facing a series of challenges in 2024, including securities fraud class action lawsuit...

CAMBRIDGE, Mass., July 02, 2024 - Biogen Inc. (Nasdaq: BIIB), a leading biotechnology and pharmaceutical company, proudly announces the completion of its acquisition of Human Immunology Biosciences (HI-Bio). This privat...

In recent news surrounding Biogen Inc., a leading biotechnology company, several events and developments have caught the attention of investors and analysts. This article aims to provide an extensive overview of these n...

In a significant development for Alzheimer s disease patients, the drug LEQEMBI (Lecanemab) has been launched in China. China now becomes the third country after the United States and Japan to introduce this promising t...

In a recent development, Biogen Inc. has received approval from the European Commission (EC) for their biosimilar monoclonal antibody called TOFIDENCE™. Referencing the well-established drug ROACTEMRA, TOFIDENCE has gai...